Atlas Trials

Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer

Clinical trial NCT06355037 · UNKNOWN

Trial details

NCT number
NCT06355037
Sponsor
Fudan University
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Triple-negative Breast Cancer
Start date
2024-05-20
Primary completion
2024-12-31
Enrollment
10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.